Welcome to our dedicated page for Longeveron news (Ticker: LGVNR), a resource for investors and traders seeking the latest updates and insights on Longeveron stock.
Longeveron Inc. (LGVNR) is a clinical-stage biotechnology pioneer developing cellular therapies for chronic conditions including Alzheimer’s disease, aging-related frailty, and congenital heart defects. This dedicated news hub provides investors and stakeholders with essential updates on the company’s scientific advancements and regulatory progress.
Access timely reports on clinical trial developments, FDA designations like Regenerative Medicine Advanced Therapy (RMAT), and strategic collaborations. Our curated collection features press releases about therapeutic innovations, peer-reviewed research publications, and milestone achievements in Longeveron’s pipeline.
Key content areas include updates on the company’s allogeneic stem cell therapies, progress across Phase 1/2 trials, and analyses of market-moving developments. Each update is vetted for relevance to long-term investors and researchers tracking cellular medicine breakthroughs.
Bookmark this page for streamlined access to LGVNR’s latest verified announcements. For comprehensive tracking of this innovative biotech’s journey in regenerative medicine, revisit regularly as new information becomes available.
Longeveron (NASDAQ: LGVN) reported its Q1 2024 financials, highlighting significant progress in clinical trials for its lead candidate, Lomecel-B™. Notably, the Phase 2b trial for HLHS is on track for completion by 2024 end. Data from a Phase 2a Alzheimer's trial will be presented at the 2024 Alzheimer’s Conference, showing promising results. Financials show a 96% revenue increase to $0.5 million, driven by the Bahamas Registry Trial, and an 8% reduction in operating expenses. The company raised $11.4 million in April, bolstering its cash reserves to $2.3 million, which is expected to fund operations through Q4 2024.
Longeveron Inc. (NASDAQ: LGVN) announced planned transitions on its Board of Directors, welcoming Richard Kender, a retired Merck executive, and nominating Dr. Roger Hajjar and Neha Motwani as new board candidates. Existing directors Joshua Hare and Ursula Ungaro are up for re-election. Jeffrey Pfeffer and Cathy Ross have resigned voluntarily. These changes aim to bring in new, experienced leaders to enhance Longeveron's therapeutic development programs.
Longeveron Inc. (NASDAQ: LGVN) will report its first quarter 2024 financial results and provide a business update on May 14, 2024. The company, a clinical stage biotechnology firm focusing on regenerative medicines, will host a conference call and webcast at 5:00 p.m. ET the same day.
